NRG NCORP General Session

PIs

Deborah Watkins Bruner, RN, PhD, FAAN

@DeborahWBruner1

and

Joan Walker, MD

Associate PI

Lisa Kachnic, MD, FASTRO
## Open NRG NCORP Trials

<table>
<thead>
<tr>
<th>Study No</th>
<th>Disease Site</th>
<th>Description</th>
<th>Date Activated</th>
<th>Target Accrual</th>
<th>Total Accrual</th>
<th>NCORP Accrual (%)</th>
<th>Expected Closure Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG CC005</td>
<td>GI</td>
<td>FORTE – Five- or Ten-Year Colonoscopy for 1-2 Non-advanced Adenomatous Polyps</td>
<td>10/6/21</td>
<td>9500</td>
<td>768</td>
<td>81%</td>
<td>June 2033</td>
</tr>
<tr>
<td>NRG CC008</td>
<td>Ovarian</td>
<td>Non-randomized prospective trial comparing non-inferiority of Salpingectomy to salpingo-Oophorectomy to Reduce the risk of Ovarian Ca among BRCA1 carriers (SOROCk)</td>
<td>6/23/20</td>
<td>2262</td>
<td>363</td>
<td>20%</td>
<td>February 2033</td>
</tr>
<tr>
<td>NRG CC009</td>
<td>Brain</td>
<td>SRS vs. HA-WBRT for 10 or Fewer Brain Metastases from Small Cell Lung Cancer</td>
<td>2/24/21</td>
<td>200</td>
<td>57</td>
<td>45%</td>
<td>September 2028</td>
</tr>
<tr>
<td>NRG CC0010</td>
<td>Endo</td>
<td>Ph III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer</td>
<td>9/19/22</td>
<td>428</td>
<td>26</td>
<td>39%</td>
<td>January 2033</td>
</tr>
</tbody>
</table>

(accred as of 7/18/23)
## Developing NRG NCORP Trials

<table>
<thead>
<tr>
<th>Study No.</th>
<th>Protocol/Concept</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-CC0011</td>
<td>Cognitive Training for Cancer-related Cognitive Impairment: A Multi-Center Randomized Controlled Trial</td>
<td>Anticipated activation late Q4 2023</td>
</tr>
<tr>
<td>Diane Von Ah, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC012CD</td>
<td>Managing symptoms and psychological distress during oral anticancer treatment</td>
<td>Protocol submitted to DCP</td>
</tr>
<tr>
<td>Alla Sikorski, PhD, Terry Badger, PhD; Tracy Crane, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC2137CD</td>
<td>Exercise is Medicine in Medical Oncology</td>
<td>R01 resubmission July 2023</td>
</tr>
<tr>
<td>Kathryn Schmitz, PhD; Jennifer Trilk, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC2324</td>
<td>Prospective single arm, Ph II trial of concurrent chemoRT with the radioprotector BMX-001 in patients with HNSCC receiving concurrent chemoRT</td>
<td>Concept reviewed by DCP 6/20/23, revisions required</td>
</tr>
<tr>
<td>David Brizel, MD; Sue Yom, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC2313</td>
<td>American Ginseng as a Treatment for Cancer-Related Fatigue</td>
<td>R01 submission October 2023</td>
</tr>
<tr>
<td>Noël Arring, DNP, PhD, RN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC2325</td>
<td>Randomized phase 3 study comparing TMPRT vs standard RT with TMZ for elderly patients with newly diagnosed MGMT-unmethylated glioblastoma to prolong symptom deterioration-free survival</td>
<td>Concept submitted to DCP for July 25, 2023 review</td>
</tr>
<tr>
<td>Jiayi Huang, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-CC2327</td>
<td>Radiation therapy for high-risk asymptomatic bone metastases: A pragmatic multicenter randomized phase III clinical trial</td>
<td>Pending concept submission to DCP</td>
</tr>
<tr>
<td>Erin F Gillespie, MD MPH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### NCORP Concept Review

<table>
<thead>
<tr>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II randomized, double blind, placebo-controlled trial of Avmacol to evaluate rates of second primary tumor formation in patients with a history of tobacco associated head and neck squamous cell carcinoma (HNSCC) – Sid Sheth, MD</td>
<td>NCORP concept review July 21, 2023</td>
</tr>
<tr>
<td>WRITE Symptoms 4 Self-Management: A Hybrid Type Effectiveness Trial of the Self-Directed WRITE Symptoms Intervention for Survivors Living with Advanced or Recurrent Gynecologic Cancers – Heidi Donovan, PhD, RN</td>
<td>NCORP concept review July 21, 2023; anticipate R01 submission September 2023</td>
</tr>
</tbody>
</table>
NRG NCORP RESOURCES
New Process for NCORP Pilot Projects

NRG NCORP will host a workshop during the NRG winter meeting, February 2024.

**Workshop goal:** to prepare investigators to develop committee aim-aligned NCORP pilot projects that would potentially lead to a larger NCORP concept.

- NCORP committee chairs will review LOIs and select those best aligned with the committee goals, NCORP priorities, and deemed most feasible for future Phase II – III NCORP concepts.
- Selected investigators will be invited to attend a workshop during the winter NRG meeting.

The LOI process is a prerequisite for pilot grant application submission for 2024.

- The request for funding application (RFA) for NCORP pilot projects will be released in Spring 2024.
- While workshop selection and enrollment does not guarantee pilot funding, the activities are designed to facilitate successful submissions.

Announcement coming soon!
NRG Health Equity Fellowship Program

The Health Equity Fellowship Program outlines three strategic, high-level goals to provide a broader perspective in clinical trials research:

1. Increase representation from diverse backgrounds with emphasis on recruitment of researchers from historically underrepresented groups (HUGs), as defined by the NIH.

2. Mentor selected early-stage NRG Oncology investigators in clinical trials education and training. The program provides networking opportunities and pathways to leadership for HUGs.

3. Develop successful clinical trials scientists who can compete in grant writing opportunities.

New applications will be accepted Fall 2023

Read more about this opportunity at: https://www.nrgoncology.org/Health-Equity-Fellowship
NRG NCORP
Biospecimens Available!

- **Tamoxifen Breast Cancer Prevention Trial (BCPT): NSABP P-1 Study**
  
  enrolled 13,388 pre-and postmenopausal women aged 35 years and older who were at an increased risk for breast cancer to receive tamoxifen or placebo for 5 years (1992 – 1997)

- **Study of Tamoxifen and Raloxifene (STAR) NSABP P-2 Study**
  
  enrolled 19,490 women at least 35 years of age and postmenopausal at increased risk for breast cancer to receive tamoxifen or raloxifene for 5 years (1999 - 2004)
Committee Transitions

CPC Committee

Debra Barton, PhD, RN
Research Professor
University of Tennessee
School of Nursing
NRG Oncology
Cancer Control Vice-Chair
August 2019 – July 2023

Tracy Crane, PhD, RDN
Associate Professor
Miller School of Medicine
Co-Leader,
Cancer Control Research Program
University of Miami
NRG Oncology
Cancer Control Vice-Chair
Beginning August 1, 2023

HDR Committee

Chanita Hughes-Halbert, PhD
Professor and Vice Chair of research in the
Department of Population and Public Health
Sciences, Associate Director for Cancer
Equity, Keck School of Medicine of USC
NRG Oncology
Health Disparities Research
Vice-Chair
June 2019 – September 2023
Seeking Vice-Chair, NRG Oncology NCORP Health Disparities Research Committee

June 28, 2023

Application Deadline: August 1, 2023

We are seeking nominations for the position of Vice-Chair of the NRG NCORP Health Disparities Research (HDR) committee. The successful candidate will work closely with the chair, Dr. Jennifer Wenzel and provide support to lead the HDR committee. The overarching goal of NRG HDR is to understand and address health disparities in an effort to reduce the unequal burden of cancer in the United States. Candidates for this position should have a track record of funding and/or publications in successful methods to improve access to clinical trials in historically underserved populations. The candidate should demonstrate a passion to elevate and nurture cancer equity, ensuring that NRG Oncology trials prioritize health and cancer outcomes for all patients, families, and communities. Further, the candidates should have documented achievements in mentorship and a willingness to provide timely consultation to members and liaisons of NRG committees as concepts and protocols are being developed.

NRG Oncology Committee Chairs and Vice-Chairs must be at an NRG Oncology Member Institution and eligible to receive federal funding. Nominal funds from federal grants to offset related effort and travel to NRG Oncology meetings is provided.

Applicants for the position should forward a cover letter addressing your specific interests and qualifications for the role as listed above, as well as your NIH biosketch to committee-nominations@nrgoncology.org. The deadline for the application submission is August 1, 2023. If you have questions about the position, forward those to the same email and we will have an appropriate party get back to you.
Stay Engaged in NRG Oncology

@NRGOnc, @FORTESStudy

@NRGOnc, @FORTESStudy

@NRG Oncology

@NRG Oncology